Introduction {#s1}
============

CRISPR-Cas systems enable adaptive immunity in prokaryotes in three stages ([@bib3]). First, molecular memories of infection are formed by the acquisition of short segments of foreign nucleic acids, which are stored as 'spacers' in CRISPR arrays (*adaptation*) ([@bib8]; [@bib22]). Second, these CRISPR arrays are transcribed into precursor transcripts, then processed into CRISPR RNAs (crRNA *processing*) ([@bib4]; [@bib21]). Finally, the crRNAs form complexes with CRISPR-associated (Cas) proteins that execute a variety of protective responses against matching nucleic acid targets (*interference*) ([@bib38]). Thus, CRISPR-Cas systems function as sequence-specific nucleases that degrade invasive genetic elements.

CRISPR-Cas loci have been organized into six phylogenetic types ([@bib31]; [@bib44]). All characterized CRISPR-Cas systems utilize crRNAs for sequence-specific identification of targets. However, different types exhibit varying modes of target interference. Type I, type II, and type V systems use crRNAs to guide the recognition and destruction of DNA targets ([@bib3]; [@bib4]; [@bib58]), whereas crRNA-guided recognition of RNA targets occurs in type VI systems ([@bib1]). In type III systems, the interference complex recognizes nascent RNA transcripts containing the reverse complement of the crRNA sequence, and degrades both the transcript and its template DNA in a process termed transcription-dependent DNA interference ([@bib32]; [@bib15]; [@bib16]; [@bib7]; [@bib14]; [@bib53]; [@bib37]; [@bib41]). Thus, interference can only occur if type III crRNAs, and hence spacers, are antisense to their cognate RNA targets. CRISPR transcription is unidirectional; as such, new type III spacers must be inserted into CRISPR arrays in a specific orientation to produce crRNAs that are functional in interference.

Other CRISPR-Cas types also require integration of new spacers in one specific orientation. Type I, II, and V CRISPR-Cas systems rely on the presence of a protospacer adjacent motif (PAM) to distinguish foreign DNA targets from the host-copy of the spacer, thereby preventing lethal self-targeting of the host CRISPR loci ([@bib34]; [@bib51]; [@bib56]). A consequence of PAM-based target authentication is that spacers must be oriented such that the PAM-proximal ends of crRNAs are positioned correctly with respect to the PAM-sensing domain of the interference complex. During CRISPR adaptation in these systems, a PAM-sensing domain in the Cas1-Cas2 spacer acquisition complex ensures spacers are integrated in the correct orientation ([@bib22]; [@bib42]; [@bib55]; [@bib35]). In contrast, type III CRISPR-Cas systems typically do not rely on PAMs to prevent self-targeting, although a highly degenerate RNA sequence constraint (rPAM) has been reported in *P. furiosus* ([@bib10]). Instead, base-pairing between the CRISPR repeat-derived 5' crRNA handle and the protospacer flanking sequence has been proposed to suppress target recognition, thereby preventing self-targeting in the context of the host CRISPR array ([@bib33]). Whether, and how, spacers are oriented in type III CRISPR arrays remains unclear.

Type III CRISPR-Cas systems comprise a large and diverse group, divided into 4 subtypes (III-A, B, C, and D). Type III-A systems usually possess spacer acquisition and pre-crRNA processing factors (Cas1-Cas2 and Cas6 homologues, respectively), whereas many type III-B, C, and D systems lack these components ([@bib31]). Such systems commonly occur in genomes containing type I CRISPR-Cas loci ([@bib30]), and in many cases share 'communal' CRISPR arrays utilizing the same repeat sequences as the co-habiting type I systems. In support of this, co-immunoprecipitation experiments have confirmed the association of 'shared' crRNAs with type III interference complexes ([@bib48]; [@bib49]; [@bib9]; [@bib29]). These associations can also lead to transcription-dependent interference against protospacer-containing plasmids in *Sulfolobus islandicus* REY15A ([@bib7]) and *Pyrococcus furiosus* ([@bib10]). There are no type III-specific CRISPR spacer arrays in the *S. islandicus* and *P. furiosus* genomes; such type III interference modules have thus been proposed to stably co-reside with type I CRISPR loci, and to depend on type I factors for spacer acquisition and crRNA maturation ([@bib31]). While the frequent co-habitation of type III with type I systems could provide benefits to the host ([@bib7]; [@bib10]), the mechanistic underpinning of this evolutionary association is unknown. Moreover, the biological and ecological role(s) of interactions between evolutionarily disparate CRISPR-Cas systems remain unexplored.

Recently, we showed that the *Marinomonas mediterranea* MMB-1 type III-B system uses a reverse transcriptase (RT)-Cas1 fusion protein to acquire spacers directly from RNA molecules ([@bib45]). The *M. mediterranea* genome contains a type I-F and a type III-B system, each with a full complement of spacer acquisition, processing, and interference components. Furthermore, each system possesses its own CRISPR loci, with distinct repeat sequences. Here, we show that the *M. mediterranea* type III-B effector complex naturally utilizes crRNAs from both type III-B and type I-F CRISPR loci for interference, despite their divergent CRISPR repeat sequences. We demonstrate that this surprising plasticity in crRNA selection allows the type III-B interference machinery to use type I-F spacers to counter infection from natural *M. mediterranea* phages abundant in the native host ecosystem, which have escaped the type I-F defenses through genetic (PAM) mutations. Based on the analysis of the sequences of highly related bacterial strains, we propose that some type III-B systems exhibiting plasticity in their crRNA utilization criteria behave as promiscuous modules. This flexibility in crRNA usage might serve as an important trait for their selection following horizontal transfer into bacterial hosts that are challenged by phages that had escaped their type I CRISPR-Cas defenses.

Results {#s2}
=======

Transcription-dependent degradation of DNA by the *M. mediterranea* type III-B CRISPR-Cas system {#s2-1}
------------------------------------------------------------------------------------------------

The *M. mediterranea* MMB-1 genome contains type III-B and type I-F CRISPR-Cas systems ([Figure 1A](#fig1){ref-type="fig"}). We examined the interference mechanism for the type III-B system using a conjugation-based plasmid interference assay. Each of the plasmids tested contained a target sequence matching either the first or second native spacer from the type III-B CRISPR array (CRISPR03) inserted in either the sense or antisense orientation relative to a constitutive promoter (P~amp~). We flanked the target sequences with either the native CRISPR repeats or randomized sequences with identical base composition ([Figure 1B](#fig1){ref-type="fig"}). Consistent with transcription-dependent DNA interference, the conjugation efficiency was reduced only when the reverse complements of the spacer sequences were transcribed from the plasmid ([Figure 1C](#fig1){ref-type="fig"}; also see [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). As expected for type III self vs non-self discrimination, CRISPR repeat sequences flanking the target protected against interference ([@bib33]).

![Transcription-dependent plasmid elimination by the *M. mediterranea* type III-B CRISPR-Cas system.\
(**A**) Schematics of the type III-B (above; adapted from \[[@bib45]\]) and type I-F (below) CRISPR-Cas systems in *M. mediterranea* MMB-1. The type III-B operon contains genes encoding the adaptation proteins RT-Cas1 and Cas2, a 6-gene *cmr* cassette encoding the type III-B effector complex, the 58-spacer CRISPR02 array, the 8-spacer CRISPR03 array, and two genes of unknown function (Marme_0670, 0671). The Cas10 HD nuclease domain, required for DNA interference in some type III-B systems ([@bib10]), is not evident in the *M. mediterranea* Cas10 (Cmr2). The entire operon is flanked by two \~200 bp direct repeats (green arrows). The type I-F system contains *cas1*, *cas2-3,* four *csy* genes and a 52 spacer CRISPR04 array. Marme_3330, 3329, and 3326 are ORFs of unknown function. The 37-spacer CRISPR05 array, located \~250 kb away from the type I-F system has a near-canonical type I-F repeat sequence but no neighboring *cas* genes. An alignment of predicted 5'-crRNA handles (last 8 nt) from type I-F and type III-B CRISPR repeats is shown, with the remaining repeat nucleotides aligned separately (grey) and the crRNA processing sites depicted by the yellow triangle. (**B**) Overview of the plasmid interference assay using native CRISPR03 spacers. Configurations that allow the protospacer RNA to be targeted by the corresponding endogenous crRNA-Cmr complex lead to plasmid elimination and cell death on selective medium (+Kan). Inactivation of the type III-B CRISPR-Cas system results in plasmid stability and a corresponding increase in transconjugants. Numbers shown correspond to colony forming units per microliter (cfu/μl) measurements from the conjugations depicted. (**C**) Transcription-dependent plasmid interference in various *M. mediterranea* mutants using native CRISPR03 spacers. Log-transformed cfu/ml measurements from conjugations of plasmids with different protospacer configurations (relative to P~amp~). Random R1 and R2 (pink text) are two different randomized sequences with base composition identical to the type III-B CRISPR repeat (brown text; CRISPR03-R). Upside down text denotes the reverse-complement. The GFP-Cmr2 strain is a control for the process of mutant construction.\
10.7554/eLife.27601.004Figure 1---source data 1.Colony forming units per mL (cfu/ml) counts obtained from conjugations for plasmid interference assays.Each box represents an independent conjugation. Assay detection limits are reported for conjugations where no viable transconjugants were observed. TMTC denotes the conjugation produced 'too many \[colonies\] to count'. The protospacer configuration of each plasmid is represented in the 'Plasmids' column. Protospacers matching the first or second spacer sequences from the III-B or I-F arrays were used as indicated. RC denotes that the reverse complement of a particular configuration was used. DR signifies that the protospacer was flanked by CRISPR repeats of the same array as the spacers.](elife-27601-fig1){#fig1}

To test the hypothesis that the observed interference was due to type III-B activity on DNA, we repeated the assays in several *M. mediterranea* mutants. Interference was not detected when genes encoding the type III-B effector complex were removed (Δ*cmr*) or when the entire type III-B operon was deleted (ΔIII-B) ([Figure 1C](#fig1){ref-type="fig"}). Additional mutational analysis indicated roles for both *cmr2* and *cmr4* in interference. Similarly, mutation of the conserved GGDD motif (Cmr2:GGAA) within the PALM domain in the Cas10-family member Cmr2 abolished interference ([Figure 1C](#fig1){ref-type="fig"}), as observed in other systems ([@bib17]). We also tested the requirement for a conserved Asp residue in Cmr4 that has been reported to be necessary for target RNA degradation, but not for DNA interference ([@bib41]). In agreement, the *M. mediterranea* Cmr4 D26A mutant was capable of transcription-dependent DNA interference ([Figure 1C](#fig1){ref-type="fig"}; also see [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

To examine whether the type III-B system was dependent on the type I-F locus, we tested type I-F deletion mutants. Removal of the type I-F operon (∆I-F) had no effect on interference of the plasmids targeted by the type III-B system. Likewise, deletion of the type I-F CRISPR array (ΔI-F CRISPR04), or deletion of the spacer acquisition and effector nuclease genes *cas1* and *cas2-3* (ΔI-F Cas123) had no effect. Simultaneous deletion of both type I-F and III-B operons abrogated plasmid interference ([Figure 1C](#fig1){ref-type="fig"}). Our results demonstrate that the *M. mediterranea* type III-B system facilitates transcription-dependent target DNA interference with no requirement for the type I-F locus.

Promiscuous capacity for spacer acquisition: absence of a concerted mechanism to orient new type III spacers {#s2-2}
------------------------------------------------------------------------------------------------------------

The transcription-dependent DNA interference we observed for the type III-B system implied that, to be functional, spacers would need to be inserted into the CRISPR array in a specific direction, such that crRNAs are complementary to their RNA targets. We previously showed that overexpression of the type III-B CRISPR adaptation components ([Figure 2A](#fig2){ref-type="fig"}) in *M. mediterranea* can facilitate spacer acquisition from cellular RNAs and DNAs ([@bib45]). In wild type, the new spacers appear to be predominantly acquired from RNA, as evident from the transcriptional bias observed with over-expression of RT-Cas1 but not RTΔ RT-Cas1 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) -- the role of RNA as the source of spacers, rather than transcribed DNA, was deduced previously ([@bib45]). However, the spacers acquired with WT RT-Cas1 showed a bias toward the orientation that would result in the generation of non-functional crRNAs that were not complementary to source mRNAs ([Figure 2B](#fig2){ref-type="fig"}). We reasoned that the observed bias could be a consequence of autoimmunity, as spacers yielding crRNAs complementary to cellular transcripts would be lethal ([@bib51]; [@bib54]). Thus, any mechanism for the acquisition of functional spacers (that are antisense to host mRNAs) would likely be masked by the presence of the native type III-B interference module.

![Interference-dependent strand bias in newly acquired spacers.\
(**A**) Arrangement of the type III-B CRISPR adaptation genes encoding Marme_0670, RT-Cas1, and Cas2 on a pKT230 broad-host-range vector under control of the putative 16S rRNA promoter (Adapted from \[[@bib45]\]). (**B**) Proportion of newly acquired spacers isolated from CRISPR03 mapping to sense and antisense strands of host genes. Strains with the entire type III-B CRISPR-Cas operon deleted (ΔIII-B), the six *cmr* genes deleted (Δ*cmr*), or wildtype (WT) were tested with overexpression of WT or RT-deleted (RTΔ) versions of RT-Cas1. (**C**) Strand bias measurements of new spacers in additional mutants with overexpression of WT RT-Cas1. Data for WT and ΔIII-B strains redrawn from (**B**) for comparison. (**B--C**) As the WT-to-∆III-B comparison was most critical, these two measurements were repeated in eight samples for each genotype, with bars for standard error of the mean (SEM) shown. Other measurements were repeated twice, with bars indicating range. Blue dashed lines denote the expectation of no bias (no bias would yield \~44.3% \[not 50%\] because spacers mapping to regions outside of annotated genes \[\~11.4% of the total genome\] provide us with no basis for strand assignment). Asterisks denote statistical testing was performed for the WT and ∆III-B datasets (p\<0.001; T-test).](elife-27601-fig2){#fig2}

Consistent with this, the ΔIII-B and Δ*cmr* mutants displayed RNA-derived spacer acquisition with a moderate bias toward spacers targeting the antisense strand of target genes ([Figure 2B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), that is, the presence of the type III-B targeting module did indeed skew detection of the acquisition of antisense spacers in the assays with wildtype (WT). Despite the clear shift in bias in the absence of type III-B interference, antisense spacers did not constitute the overwhelming majority; arguing against a strong, concerted mechanism to orient incoming spacers into the CRISPR array. Moreover, the strand bias entirely disappeared when the RT-deleted version of RT-Cas1 (RTΔ RT-Cas1) was supplied ([Figure 2B](#fig2){ref-type="fig"}), thereby highlighting an intrinsic difference between spacer acquisition from RNA and DNA sources (RTΔ RT-Cas1 has previously been shown to acquire spacers only from DNA \[[@bib45]\]). Finally, we tested whether the strand bias of newly acquired spacers in other CRISPR-Cas mutants was consistent with their interference capabilities. With over-expressed WT RT-Cas1, all strains supported spacer acquisition from host RNAs ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). As expected, the mutants capable of plasmid interference showed a bias for spacers matching the sense strand of source RNAs. Conversely, mutants incapable of interference showed a moderate bias for spacers matching the reverse complement of the source RNA ([Figure 2C](#fig2){ref-type="fig"}). In summary, the orientation of new type III-B spacers bears only a partial relationship to the strandedness of the source transcript. Additionally, host-derived spacers integrated in the antisense orientation are negatively selected in the presence of type III-B interference, due to transcription-dependent autoimmune self-targeting.

*M. mediterranea* type I-F spacers provide protection against an abundant marine phage {#s2-3}
--------------------------------------------------------------------------------------

To evaluate type III-B targeting in an ecological context, we isolated *M. mediterranea* phages from the original source of the MMB-1 strain in seawater from *Posidonia oceanica* seagrass meadows off the Mediterranean coast in south-eastern Spain. An enrichment culture from environmental samples from the coast of Cabo de Palos yielded plaques on lawns of the ΔIII-B *M. mediterranea* strain. The genomes of two phages, CPG1g and CPP1m (which produced plaques with different sizes) were sequenced, assembled, and annotated. The two \~44 kb genomes differ at only 7 sites, indicating that they are polymorphic variants of the same virus (also see Materials and methods). An additional 25 phage isolates were confirmed as likely variants of CPG1g using PCR probes designed against conserved regions in phage genes (data not shown). *Marinomonas* phage CPG1g has a 44,244 bp double stranded DNA genome. It contains 50 predicted open reading frames and one tRNA (Arg). Phylogenetic analyses based on the DNA polymerase protein sequence revealed that CPG1g belongs to the SP6 cluster within the T7 supercluster of the *Podoviridae* family and is most closely related to *Vibrio* phage Vc1 ([@bib26]) and Ø318 ([@bib27]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The only *Marinomonas* phage described previously belongs to the *Siphoviridae* family ([@bib23]). In agreement with a classification as a podovirus, electron microscopy revealed that CPG1g/CPP1m possess a very short tail ([Figure 3A](#fig3){ref-type="fig"}). Other *M. mediterranea* strains (IVIA-Po-186 ([@bib11]) and CPR1 (this study)) are sensitive to CPG1g infection, whereas the most closely related species of the same genus (*M. balearica* IVIA-Po-101; ([@bib11])), as well as other marine bacteria (*Pseudoalteromonas tunicata* and *Vibrio harveyi*) are resistant, indicating a narrow host range.

![Phage-derived type I-F spacers are utilized by type III-B interference machinery.\
(**A**) Transmission electron micrograph (TEM) of phage CPP1m stained with uranyl acetate. (**B**) CPG1g plaques on lawns of WT (left) and ΔIII-B (right) strains. (**C**) The type I-F CRISPR04 array contains spacers with near-perfect 32 bp matches to portions of the CPG1g RNA polymerase and the T7p06-like genes, and a third spacer with 5 mismatches (including a mutation in the 'seed' region) to a target in a gene encoding a hypothetical protein. CPG1g bases at the positions of the canonical type I-F PAM are highlighted in green. crRNAs from both near-perfect spacers 1 and 2 would be complementary to the putative phage mRNAs, while the mismatched 3rd spacer would yield crRNAs unable to bind targeted phage mRNA (denoted by inverted alignment). (**D**) Susceptibility of *M. mediterranea* mutants to CPG1g. Efficiency of plaquing is calculated as the fold change in counts of plaque forming units (PFU) relative to WT. Bars indicate results from 2 independent trials. § denotes enlarged plaques. (**E**) Transcription-dependent plasmid interference in various *M. mediterranea* mutants using native CRISPR04 spacers. Log-transformed cfu/ml measurements from conjugations of plasmids with various protospacer configurations. Type I-F spacer-matching sequences are flanked either by 28 bp of phage-derived sequence (pink text), or by 28 bp type I-F CRISPR repeats (brown text; CRISPR04-R). Upside down text denotes the reverse-complement.\
10.7554/eLife.27601.010Figure 3---source data 1.Colony forming units per mL (cfu/ml) counts obtained from conjugations for plasmid interference assays.Each box represents an independent conjugation. Assay detection limits are reported for conjugations where no viable transconjugants were observed. TMTC denotes the conjugation produced 'too many \[colonies\] to count'. The protospacer configuration of each plasmid is represented in the 'Plasmids' column. Protospacers matching the first or second spacer sequences from the III-B or I-F arrays were used as indicated. RC denotes that the reverse complement of a particular configuration was used. DR signifies that the protospacer was flanked by CRISPR repeats of the same array as the spacers.](elife-27601-fig3){#fig3}

CPG1g infection of the ΔIII-B mutant was \~10 fold more productive than in WT, with substantially larger plaques in the ∆III-B deletion ([Figure 3B,D](#fig3){ref-type="fig"}). This suggested a role of the type III-B CRISPR-Cas system in defense against CPG1g infection. Therefore, we scanned the phage genome for sequences matching spacers in each of the *M. mediterranea *MMB-1 CRISPR arrays. Surprisingly, none of the type III-B CRISPR spacers matched the phage genome, but the first two spacers in the type I-F CRISPR04 array had perfect or near-perfect matches to CPG1g ([Figure 3C](#fig3){ref-type="fig"}); the mismatch at position 6 for the first spacer is not expected to impair targeting efficiency in type I-F systems ([@bib54]; [@bib5]). Both near-perfect CPG1g-targeting spacers mapped to the antisense strand of predicted viral ORFs, indicating that they may be compatible with type III-B transcription-dependent interference ([Figure 3C](#fig3){ref-type="fig"}). In addition, the third type I-F CRISPR04 spacer weakly matched the phage genome (5 mismatches, including one in the 'seed' region previously shown to be critical for binding of the type I-F interference complex \[[@bib57]\]) and had a sense (instead of antisense) orientation relative to the putative phage transcripts.

To test the role of the two CRISPR-Cas systems in defense against CPG1g, we measured the efficiency of plaquing (EOP) on strains lacking the type I-F and type III-B loci (∆I-F, ∆III-B, and ∆I-F∆III-B). All three strains displayed an increase in phage sensitivity ([Figure 3D](#fig3){ref-type="fig"}), suggesting that there might be interplay between the two systems. Therefore, we removed the type I-F *cas1* and *cas2-3* genes without removal of the type I-F CRISPR04 array or *csy* genes (ΔI-F Cas123). This mutant strain was not impaired in defense against CPG1g, demonstrating that phage resistance was not dependent on either the effector nuclease or spacer acquisition machinery of the type I-F system. These observations suggest cooperation between the interference machinery of the type III-B system and the CRISPR array of the type I-F system in providing defense against CPG1g infection.

Cross-talk between the type III-B system and the type I-F CRISPR array {#s2-4}
----------------------------------------------------------------------

As an independent method of assessing type I-F spacer-directed targeting by the type III-B system, we used the plasmid interference assay described earlier, except with target sequences derived from the portions of the CPG1g genome that matched the type I-F spacers 1 or 2. Consistent with transcription-dependent type III-B function, rather than type I-F DNA targeting, we observed interference only when the reverse complement of the spacer-matching sequence was transcribed ([Figure 3E](#fig3){ref-type="fig"}; also see [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Moreover, we did not observe transcription-dependent interference when either the type III-B targeting module was disrupted or the type I-F CRISPR04 array was removed. Flanking the target sequence with type I-F CRISPR repeat sequences abrogated plasmid interference. Thus, despite the sparse similarity between the type I-F and type III-B repeat sequences ([Figure 1A](#fig1){ref-type="fig"}), the self/non-self discrimination mechanism of the type III-B system was still able to function. Confirming our finding that the type I-F effector nuclease (Cas3) was not required for resistance to CPG1g, deleting the type I-F *cas1* and *cas2-3* genes did not abolish transcription-dependent plasmid elimination ([Figure 3E](#fig3){ref-type="fig"}).

The type III-B system uses pre-processed crRNAs from the type I-F system {#s2-5}
------------------------------------------------------------------------

Initially, we hypothesized that the type III-B system was capable of processing the type I-F pre-crRNA transcribed from the CRISPR04 array ([Figure 4A](#fig4){ref-type="fig"}). The genes encoding the type III-B pre-crRNA processing activity in *M. mediterranea* have not previously been identified, and the operon lacks a clear *cas6* homologue. Therefore, we tested whether the processing activity resided in the CRISPR adaptation components (RT-Cas1, Cas2, Marme_0670), as it was unlikely to reside in the six Cmr genes, and the only other gene in the operon -- *marme_0671* -- could not be easily tested because its overexpression led to toxicity. We expressed the adaptation components in the ΔIII-B and ΔI-FΔIII-B strains, and assayed for crRNA processing by small-RNA sequencing. Controls with only the CRISPR03 array supplied were also included. Pre-crRNA from the type III-B CRISPR03 array was processed efficiently in the ΔIII-B strain only when the type III-B adaptation components were supplied ([Figure 4B--E](#fig4){ref-type="fig"}). Thus, the factor(s) required for type III-B pre-crRNA processing do indeed reside in the supplied CRISPR adaptation module. Moreover, this demonstrates that the chromosomally-encoded type I-F factors (left intact in the ΔIII-B strain) could not process type III-B CRISPR03 pre-crRNA. In contrast, type I-F pre-crRNA was processed efficiently in the ΔIII-B strain, irrespective of the presence of the plasmid-encoded type III-B adaptation genes ([Figure 4F,G](#fig4){ref-type="fig"}).

![Type I-F and type III-B pre-crRNA processing in *M. mediterranea*.\
(**A**) Alignment of type I-F CRISPR repeat sequences from CRISPR04 and CRISPR05 (see [Figure 1A](#fig1){ref-type="fig"}). Yellow triangle marks the expected pre-crRNA processing site 8 nt upstream of 3' end of the CRISPR04/05 direct repeat sequence. (**B--I**) Processed crRNA levels assayed by high throughput small RNA sequencing. Each dataset includes RNA sequences from two separate transconjugants. The presence of a distinct 3' end sequence in the population of CRISPR repeat containing RNAs indicates site-specific cleavage and processing of pre-crRNA. Counts are normalized to Isoleucine tRNA levels (consistently the most abundant species encountered). Type III-B adaptation components -- RT-Cas1, Cas2, Marme_0670 genes and the CRISPR03 array -- were supplied in (**C, E, G, I**), whereas only the CRISPR03 array was supplied in (**B, D, F, H**). The genetic background of the host strain is indicated in the figure. The CRISPR04 repeat sequence is shown in (**F--I**) for simplicity, but read counts from both type I-F CRISPR arrays are included in the figures.](elife-27601-fig4){#fig4}

The type I-F CRISPR04 crRNA signal is expected to be absent in the ΔI-FΔIII-B strain, because the type I-F operon deletion removed the entire CRISPR array (CRISPR04) and the pre-crRNA-processing factor Cas6f (Csy4) ([Figure 4H](#fig4){ref-type="fig"}). However, processed crRNAs from the type I-F orphan CRISPR05 array (see [Figure 1A](#fig1){ref-type="fig"}) were readily observed in the ΔIII-B strain, but not in the ΔI-FΔIII-B strain, regardless of whether type III-B adaptation genes were supplied ([Figure 4I](#fig4){ref-type="fig"}; also see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These findings show that in the absence of Cas6f (Csy4), the type III-B processing machinery is not capable of generating mature crRNAs from type I-F CRISPR arrays. Thus, the processing machineries of both CRISPR-Cas systems are independent and specific to their respective CRISPR repeats. Taken together with the earlier results, this shows that the type III-B interference complex promiscuously obtains mature type I-F crRNAs, and can use them for transcription-dependent interference.

PAM evasion allows escape from type I-F but not type III-B systems {#s2-6}
------------------------------------------------------------------

The failure of the type I-F system to use its pre-existing spacers to combat CPG1g infection could be due to silencing of the type I-F system by phage- or host-encoded anti-CRISPRs, chemical modification of phage DNA, mutational escape by the phage, or atrophy of the type I-F system. Type I-F systems typically use GG PAMs ([@bib34]; [@bib40]), whereas the PAMs present in CPG1g for the targets of CRISPR04 spacer 1 and spacer 2 are AG and TG, respectively ([Figure 3C](#fig3){ref-type="fig"}). To test whether the *M. mediterranea* type I-F system was active and uses canonical GG PAMs, we repeated our plasmid interference assay using the phage-derived target sequences, except with the putative GG PAM restored ([Figure 5A,B](#fig5){ref-type="fig"}). In WT, we saw robust interference irrespective of the orientation of the target relative to the promoter ([Figure 5C](#fig5){ref-type="fig"}; also see [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}); this was consistent with type I-F targeting of the plasmid DNA. Furthermore, deletion of the type III-B CRISPR-Cas operon did not impair plasmid elimination, whereas removal of the type I-F operon, in isolation or conjunction with the type III-B operon deletion, abrogated interference. Deletion of the type I-F *cas1* and *cas2-3* genes resulted in interference only when the reverse complement of the spacer sequence was transcribed from the plasmid. This indicates that type III-B targeting using type I-F crRNAs occurs concurrently with the type I-F targeting, but is only evident when type I-F interference is disabled. We also examined whether the type I-F targeting module could use type III-B crRNAs, by inserting GG PAM sequences in our plasmids containing type III-B protospacers. In this case, we observed only transcription-dependent plasmid elimination that is characteristic of type III interference ([Figure 5D](#fig5){ref-type="fig"}; also see [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). While it is possible that, due to some unforeseen protective mechanisms, we failed to see transcription-independent interference in this assay, these results suggest that the type I-F targeting module is unable to reciprocally use type III-B crRNAs for DNA interference.

![Contrasting determinants for self/non-self discrimination with a single crRNA.\
(**A**) Schematic of crRNA corresponding to the first spacer of CRISPR04 bound to protospacer DNA containing the canonical type I-F GG PAM. (**B**) Experimental outline of the plasmid interference assay using native CRISPR04 spacer sequences with reconstituted canonical (GG) PAMs. Both orientations of the protospacer DNA would be targeted by Csy-bound type I-F crRNA (blue), leading to plasmid loss independent of the direction of transcription. A configuration that would allow the protospacer RNA to be targeted by the Cmr-bound type I-F crRNA would also lead to plasmid instability. Conversely, deletion of the type I-F CRISPR-Cas system removes the CRISPR04 array, and would result in viable transconjugants despite the presence of Cmr-bound type III-B crRNA (red). Numbers shown correspond to cfu/μl measurements from the conjugations depicted. (**C--D**) Log-transformed cfu/ml measurements from conjugations of plasmids with different protospacer configurations. Upside down text denotes the reverse-complement. (**C**) Plasmid interference using native CRISPR04 spacers and GG PAM. The type I-F spacer-matching sequences are flanked either by 28 bp phage derived sequence (pink text) with reconstituted GG PAMs (green text), or by 28 bp type I-F CRISPR repeats (brown text; CRISPR04-R). (**D**) Plasmid interference using native CRISPR03 spacers and GG PAM. Type III-B spacer-matching sequences are flanked by Random R1 and R2 sequences (pink text) from [Figure 2C](#fig2){ref-type="fig"} with two bases preceding the protospacer converted to GG PAM (green text), or by the type III-B CRISPR repeat (brown text; CRISPR03-R). Data for CRISPR04-R and CRISPR03-R controls redrawn from [Figures 3E](#fig3){ref-type="fig"} and [2C](#fig2){ref-type="fig"}, respectively.\
10.7554/eLife.27601.015Figure 5---source data 1.Colony forming units per mL (cfu/ml) counts obtained from conjugations for plasmid interference assays.Each box represents an independent conjugation. Assay detection limits are reported for conjugations where no viable transconjugants were observed. TMTC denotes the conjugation produced 'too many \[colonies\] to count'. The protospacer configuration of each plasmid is represented in the 'Plasmids' column. Protospacers matching the first or second spacer sequences from the III-B or I-F arrays were used as indicated. RC denotes that the reverse complement of a particular configuration was used. DR signifies that the protospacer was flanked by CRISPR repeats of the same array as the spacers. PAM signifies that the type I-F GG PAM sequence was restored. Plasmids for [Figure 5C and D](#fig5){ref-type="fig"} in boldface represent data that were reproduced from [Figures 1C](#fig1){ref-type="fig"} and [3E](#fig3){ref-type="fig"}.](elife-27601-fig5){#fig5}

By confirming that the type I-F system is active and relies on GG PAMs for target recognition, we conclude that the PAM mutations for the targets of spacer 1 and spacer 2 in phage CPG1g allow it to evade the type I-F system, and that the type III-B system is able to compensate for this. It is conceivable that sharing of spacers and specificities between CRISPR-Cas systems would result in redundancy by allowing type I spacers to be backed up in efficacy through the activity of co-occurring type III machinery. To evaluate the possible generality of such a backup process, we carried out experiments to test for spacer sharing in a substantially divergent host, *Serratia* sp. ATCC39006, that likewise carries both type I and type III CRISPR-Cas systems ([@bib12]; [@bib36]). Each CRISPR-Cas system in *Serratia* (types I-E, I-F and III-A) possesses at least one type-specific CRISPR array and spacer acquisition module. The type III-A operon encodes Cas1 and Cas2 but no RT-Cas1 fusion. To test for cross-type crRNA utilization in *Serratia*, we used a conjugation-based plasmid interference assay with targets matching native CRISPR spacers under the control of an arabinose-inducible promoter ([Figure 5---figure supplement 1A--D](#fig5s1){ref-type="fig"}). A control plasmid lacking any protospacer was not targeted, whereas a plasmid containing a type III target on the transcribed strand was subject to robust interference ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}). However, the type I-E and type I-F target-containing plasmids were only subject to interference when they possessed canonical PAMs for their respective systems ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}). Thus, the *Serratia* type III-A system does not appear to be capable of utilizing crRNAs from either the type I-E or type I-F systems.

Dynamic interchange of type III-B CRISPR-Cas loci {#s2-7}
-------------------------------------------------

We postulated that *M. mediterranea* MMB-1 once possessed type I-F-mediated immunity against the putative ancestor of phage CPG1g, and that subsequently a phage variant (such as CPG1g) with mutations in the target PAM sequences escaped the type I-F defenses. This would have led to selective advantage following acquisition of a PAM-independent CRISPR-Cas system (i.e. the type III-B operon) that was able to provide immunity against CPG1g by using the pre-existing phage-matching type I-F crRNAs. Consistent with this hypothesis, the type III-B operon in *M. mediterranea* MMB-1 is flanked by direct repeats reminiscent of integration scars ([Figure 1A](#fig1){ref-type="fig"}), suggesting that it was derived from a horizontal gene transfer event. To explore the putative mobility of this CRISPR-Cas system, we sequenced the genomes of two additional *M. mediterranea* strains -- CPR1 isolated in Cabo de Palos (same site as the source of CPG1g and close to the site of isolation of *M. mediterranea* MMB-1), and IVIA-Po-186 isolated in Porto Colom in the Balearic Islands (\~500 km away). All three strains shared \>99.7% identity in 16S ribosomal RNA sequences, and \>99% Average Nucleotide Identity (ANI) across their entire genomes, indicating that these are virtually identical strains of the same species, primarily differing in the accessory genome elements (including transposons and prophages) ([@bib24]). *M. mediterranea* CPR1 and IVIA-Po-186 possess type I-F CRISPR-Cas systems that are highly similar to MMB-1 ([Figure 6A](#fig6){ref-type="fig"}), except that none of their spacers match the CPG1g genome. This is consistent with their higher sensitivity (than MMB-1) to this virus. Although a few identical spacers were found between the CPR1 and IVIA-Po-186 strains, the overall lack of conservation of the spacer repertoire between even the cognate type I-F CRISPR arrays suggests a high diversity of invasive genetic elements in the native environments of these hosts.

![Arrangements of type I-F and type III-B CRISPR-Cas systems in *Marinomonas*.\
(**A**) Schematic of the type I-F CRISPR-Cas loci in *M. mediterranea* CPR1 and IVIA-Po-186. The numbers below genes indicate % protein sequence identity to corresponding homologs in *M. mediterranea* MMB-1. (**B**) Schematic of the type III-B loci in the *M. mediterranea* strains that we sequenced. A hypothetical common ancestor lacking any type III-B systems is shown. The *M. mediterranea* MMB-1 type III-B system is integrated between the *greB* and *mscS* genes. The same genomic locus contains a degraded CRISPR array in *M. mediterranea* IVIA-Po-186, possibly as a result of recombination between CRISPRs of an ancestral type III-B operon at this site. A different type III-B system is found in *M. mediterranea* CPR1, integrated within the molybdenum transport operon. The *greB-mscS* regions in *M. mediterranea* IVIA-Po-186 and CPR1 were confirmed by PCR and sanger sequencing. (**C**) The *Marinomonas* sp. MWYL1 genome contains a chimeric CRISPR-Cas system with *cmr* genes encoding the type III-B effector complex and the type I-F pre-crRNA processing enzyme Cas6f, along with a type I-F CRISPR array. The most similar homolog of the *Marinomonas* sp. MWYL1 Cas6f (Csy4) is encoded in the *M. gallaica* type I-F system.](elife-27601-fig6){#fig6}

Moreover, IVIA-Po-186 and CPR1 do not possess the MMB-1 type III-B operon. The CPR1 genome contains a highly divergent type III-B CRISPR-Cas system in a different genomic location to the MMB-1 type III-B operon ([Figure 6B](#fig6){ref-type="fig"}). Moreover, the repeats of the MMB1 and CPR1 type III-B CRISPR arrays are dissimilar (\~50% identity). These data are indicative of the independent horizontal acquisition of a distinct type III-B system in this strain. The IVIA-Po-186 genome contains a putatively defunct CRISPR array with degraded type III-B repeats, which is present within the same genomic context as the type III-B locus in MMB-1. This indicates that a type III-B system likely once resided in IVIA-Po-186 ([Figure 6B](#fig6){ref-type="fig"}). We hypothesize that once selective pressure for maintaining the supposed type III-B system alleviated (for example the threat of a specific phage abated), the protein-coding operon was lost due to recombination between flanking CRISPR arrays. No remnant of the MMB-1 type III-B system was found in CPR1, and no remnant of the CPR1 system was found in either MMB1 or IVIA-Po-186. Overall, our observations are in agreement with the notion that the type III-B systems in these closely related *M. mediterranea* strains were independently acquired by horizontal transfer.

Our findings support a model in which specific type III CRISPR-Cas systems can serve as promiscuous 'backup units' for type I-F adaptive immunity in *Marinomonas* species. We also analyzed the CRISPR-Cas content of previously sequenced *Marinomonas* genomes and found that *Marinomonas* sp. MWYL1 possesses a chimeric CRISPR-Cas system containing a type III-B interference module adjacent to a gene encoding the type I-F pre-crRNA processing enzyme Cas6f (Csy4) and a type I-F CRISPR array (but no type III-B Cas6 or CRISPR array; [Figure 6C](#fig6){ref-type="fig"}). There is also a type I-E system but no type III CRISPR arrays in this strain. The closest homolog of the MWYL1 Cas6f protein belongs to a bonafide type I-F operon in *Marinomonas gallaica* ([Figure 6C](#fig6){ref-type="fig"}). By searching for co-occurring *cas10* and *cas6f* genes, we identified a similar hybrid in *Shewanella putrefaciens* 200 (NC_017566). This suggests that cross-talk between type III-B and type I-F systems is not limited to *Marinomonas*. We propose that selective pressures resulting from proliferation of phage mutants that evade host type I-F defenses can drive the selection for horizontally acquired type III-B systems, and may have also resulted in selection for chimeric type III-B/Cas6f type I-F CRISPR loci in some hosts.

The type III-B CRISPR-Cas system counteracts viral escape from the type I-F system {#s2-8}
----------------------------------------------------------------------------------

We hypothesized that it might be possible to detect phages in the native ecosystem that remain sensitive to *M. mediterranea* MMB-1 type I-F interference. Therefore, we performed additional phage isolations using samples of sediment obtained from different *P. oceanica* meadows off the Mediterranean coast, with the host strain *M. mediterranea* T103 ([@bib28]) that showed high sensitivity to CPG1g in preliminary assays. Another new phage, named CB5A, was isolated and genome sequencing revealed that CB5A is a close relative of phages CPG1g/CPP1m, with only a few differences ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}). Most notably, the protospacer targeted by the second spacer in the *M. mediterranea* MMB-1 type I-F CRISPR04 array contained a canonical PAM (GG) ([Figure 7A](#fig7){ref-type="fig"}). Moreover, the protospacer in phage CB5A that matches spacer 3 in the host CRISPR04 array contains only 3 mismatches versus 5 for phage CPG1g. Therefore, we propose that CB5A more closely resembles the 'pre-escape' ancestor of CPG1g. CB5A showed almost no ability to infect WT MMB-1, with extremely small plaques forming only at very high phage concentrations (near the assay limit of detection) ([Figure 7B](#fig7){ref-type="fig"}, also see [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). In the absence of type I-F mediated defense (the ΔI-F Cas123 strain) we observed a \~50 fold increase in sensitivity to CB5A ([Figure 7B](#fig7){ref-type="fig"}), but with very small plaques ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This demonstrates that interference by the type I-F system contributes to immunity against CB5A ‒ consistent with the intact PAM for the protospacer matched by the *M. mediterranea* MMB-1 CRISPR04 spacer 2. This is in contrast to CPG1g infection (i.e. a PAM-escape mutant), where the type I-F system alone does not confer measureable immunity ([Figure 3D](#fig3){ref-type="fig"}). Moreover, deletion of the MMB-1 type III-B module resulted in a \>1000 fold increase in sensitivity to CB5A (relative to WT host) ([Figure 7B](#fig7){ref-type="fig"}). Thus, the type III-B system provides greatly enhanced defense against CB5A infection. However, CB5A 'pre-escape phage' plaques on the ∆III-B indicator strain were still smaller than those of CPG1g on the same indicator strain (compare [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"} and [Figure 3B](#fig3){ref-type="fig"}), likely due to type I-F‒mediated targeting of the PAM-containing protospacer in CB5A. Maximal sensitivity to CB5A, evident in both plaquing efficiency and plaque size, was observed when both the type I-F and type III-B systems were removed, or in the strain with the type I-F operon deleted ‒ in the latter case this is a consequence of removal of the type I-F CRISPR array containing the phage-matching spacers. These findings demonstrate that both systems participate in coordinated defense against CB5A using the type I-F crRNAs.

![The type III-B system suppresses proliferation of phage mutants that escape type I-F defenses.\
(**A**) The type I-F CRISPR04 array contains spacers with near-perfect 32 bp matches to targets in the CB5A RNA polymerase and the T7p06-like genes, and a third spacer with 3 mismatches (including a mutation in the 'seed' region) to a target in a gene encoding a hypothetical protein. CB5A bases at the positions of the canonical type I-F PAM are highlighted in green. The intact type I-F PAM (GG) at the second protospacer site is highlighted. crRNAs from both near-perfect spacers 1 and 2 would be complementary to the putative phage mRNAs, while the mismatched 3rd spacer would yield crRNAs unable to bind targeted phage mRNA (denoted by inverted alignment). (**B**) Susceptibility of *M. mediterranea* mutants to CB5A. Efficiency of plaquing (EOP) is calculated as the fold change in counts of plaque forming units (PFU) relative to WT. CB5A titers on the WT host (defined here as EOP = 1) could only be obtained at phage concentrations near the assay detection limit (100 pfu/mL). Bars indicate results from 2 independent trials. § denotes enlarged plaques. (**C**) Cultures of the WT and ∆III-B strains of *M. mediterranea* MMB-1 were inoculated with phage CB5A, and phage populations were sub-cultured the next day with fresh host cells. Phage titers were determined on WT, ∆III-B, and ∆I-F∆III-B indicator strains using the Most Probable Number method ([@bib25]). Titers of phage populations passaged on WT and ∆III-B strains are from 3 and 6 independent experiments, respectively. § denotes enlarged plaques. Asterisks denote statistically significant differences relative to the phage titers on the WT strain (p\<0.001; T-test). Phage stocks generated by passaging on WT host did not show any infectivity, even when used undiluted. Assay detection limit is indicated by dashed blue lines. (**D**) Whole genome sequencing assessment of the mutational landscape of 11 isolates of 'escape' phage from 6 evolution experiments with the ∆III-B host. The numbers of single nucleotide polymorphisms (SNPs), short insertions or deletions (indels), and large insertions, deletions, or rearrangements (structural variants) are shown. Precise chromosomal breakpoints of deletions (denoted by ∆start-end) are indicated. Corresponding mutations in the type I-F protospacer regions are also listed. Protospacers are numbered according to (**A**); the presence of a PAM, and the compatibility of the protospacer with type III-B interference (i.e. whether the type I-F crRNA is complementary to the phage mRNA) are indicated in the column headers for reference.\
10.7554/eLife.27601.020Figure 7---source data 1.Percent Identity and Similarity comparisons of protein products of homologous genes from phages CPG1g and CB5A.A score of X/Y in the last column implies that a CB5A protein is X% identical and Y% similar to its cognate CPG1g protein. Chromosomal start and end positions in the CPG1g genome are noted next to the CPG1g gene accessions. A short description of the putative gene product is also included.](elife-27601-fig7){#fig7}

To examine the conditions that led to proliferation of the CPG1g/CPP1m 'escape' phages and/or selection for the uptake and maintenance of the promiscuous type III-B system in *M. mediterranea* MMB-1, we performed an experiment to measure the frequency of phage escape in the presence or absence of type III-B immunity. Cultures of WT and ∆III-B strains were infected with CB5A, and the phage populations were passaged on fresh host cells the following day. The resulting phage titers were then determined on several host mutants. We found that the phage populations had been eliminated from the WT cultures in just one re-inoculation step, with the absence of any detectable plaque formation on any indicator strains ([Figure 7C](#fig7){ref-type="fig"}). In contrast, phage populations passaged through cultures of the ∆III-B strain yielded small plaques on lawns of the WT indicator strain, suggesting the presence of 'escape phage' ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). These phage populations displayed a \~ 5,000--10,000 fold increased EOP for infection of ΔIII-B versus WT indicator strains, and no additive effect compared with the ∆I-FΔIII-B strain ([Figure 7C](#fig7){ref-type="fig"}). Moreover, the plaque sizes were greatly increased on the ∆III-B indicator strain, unlike the original CB5A phage that produced small plaques on ΔIII-B lawns ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This indicates that passaging of CB5A in cells possessing only type I-F immunity results in rapid proliferation of phage variants that evade the host type I-F defenses. To confirm genetic changes to the phage population, we attempted to sequence the genomes of 2 escape phages isolates from each of the 6 independent evolution experiments with the ∆III-B host. All 11 successfully sequenced phage genomes contained a deletion or seed-region mutation in the PAM-containing protospacer (subject to type I-F interference), but not in the PAM-lacking protospacer, nor in the mismatched protospacer that already contained a seed mutation ([Figure 7D](#fig7){ref-type="fig"}). In all, 8 distinct escape mutations (6 large deletions spanning the entire protospacer, 1 seed substitution, 1 seed frameshift) were observed ([Figure 7D](#fig7){ref-type="fig"}). None of the escape mutations were observed across multiple independent trials of the evolution experiment, suggestive of a diversity of escape phages which could not proliferate when passaged with the WT host due to simultaneous PAM-independent type III-B targeting at both the first and second protospacers. Finally, we tested the ability of three escape phages (containing the seed mutation, the seed frameshift, and a deletion spanning the PAM-containing protospacer respectively) to infect various *M. mediterranea* mutants. We found small plaques on WT and ∆I-F Cas123 indicator strains, and large plaques on ∆III-B and ∆I-F∆III-B hosts for all three escape phages ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}), similar to the naturally occurring escape phage CPG1g. These findings confirm that in the absence of the *M. mediterranea* MMB-1 type III-B CRISPR-Cas system, phage variants that escape host type I-F immunity, such as CPG1g, can proliferate. Thus, host strains that possess, or in theory acquire, type III-B systems that can utilize existing host type I-F crRNAs, have a fitness advantage when faced with rapidly evolving threats.

Discussion {#s3}
==========

Recently, we showed that the type III-B RT-Cas1 fusion in *M. mediterranea* enables spacer acquisition directly from RNA ([@bib45]). Here we demonstrated that this system directs DNA interference in a transcription-dependent manner. Complementarity between crRNA guides and target RNA is a requirement for this mechanism, hence new spacers (whether DNA or RNA derived) need to be integrated directionally in the CRISPR array to function. By eliminating biases associated with autoimmunity, we showed that the orientation of new spacers derived from host RNAs was only marginally in favor of the functional (antisense) direction. Therefore, almost half of the RT-Cas1 acquired spacers are useless for RNA and DNA interference. This is surprising and raises the question of why higher fidelity spacer orientation mechanisms, such as observed in PAM-dependent CRISPR-Cas systems ([@bib43]; [@bib50]), have not arisen.

Characterizing *M. mediterranea* defense against phages, we uncovered an ecologically functional plasticity in crRNA selection and utilization by the type III-B interference machinery that allows for cross-talk between the (otherwise autonomous) type III-B system and spacers stored in a type I-F CRISPR array. We show that the type III-B effector complex can use type I-F crRNAs despite the stark dissimilarity between the respective CRISPR repeat sequences. Use of type I-F crRNAs by the type III-B system provides protection to *M. mediterranea* MMB-1 from infection by a phage abundant in the native environment of the host. The type I-F system contains immunological memory of the phages isolated in this study, CPG1g/CPP1m and CB5A, but is unable to provide effective defense against CPG1g due to PAM mutations in the phage genome. Type III-B interference against CPG1g (and other phage variants that 'escape' type I-F defenses) using type I-F spacers, but without requiring a specific PAM, serves as an additional line of defense for *M. mediterranea*. We found that this cross-system spacer usage is reliant on the type I-F pre-crRNA processing activity of Cas6f (Csy4). Consistent with this, a chimeric CRISPR-Cas system in the related bacterium *Marinomonas* sp. MWYL1 comprises a set of genes encoding a type III-B effector complex, with a type I-F *cas6f* gene and type I-F CRISPR array. In addition, the ability to process type I pre-crRNAs might be carried within some type III operons; for example, the type III-B system in *M. mediterranea* CPR1 encodes two diverse Cas6-family proteins ([Figure 6](#fig6){ref-type="fig"}) that may enable the system to independently process pre-crRNAs from different CRISPR-Cas systems. This would be interesting for future study.

Although it is possible that the *M. mediterranea* MMB-1 type III-B system gained the ability to use type I-F crRNAs during prolonged co-residence with the type I-F system, our comparative genomic data support an alternate theory. We propose that CPG1g escaped the defenses of a progenitor *M. mediterranaea* host -- which only contained a type I-F system -- through the acquisition of PAM mutations. Proliferation of the escape phage drove selection for *M. mediterranea* strains that had subsequently acquired the type III-B CRISPR-Cas system, which could co-opt the existing type I-F crRNAs to provide defense against CPG1g. Despite the fact that the *M. mediterranea* MMB-1 strain containing the CPG1g- and CB5A-matching spacers was isolated \~20 years ago ([@bib46]), the phage protospacer sequences do not appear to have acquired further mutations to avoid type III-B interference. Previous studies have shown that type III systems are more tolerant of mutations in their target protospacer and flanking sequences ([@bib53]; [@bib10]; [@bib33]; [@bib49]). Thus, the probability of escape from the type III system is likely to be less than for type I-F systems. Additionally, the type III-B system might provide a protective advantage to *M. mediterranea* MMB-1 without significantly affecting the phage population, which might rely on other bacterial reservoirs ([@bib19]); for example, the CPR1 and IVIA-Po-186 *M. mediterranea* isolates are sensitive to CPG1g infection.

Such 'immunological insurance' provided by mobile CRISPR-Cas modules might be generalizable to other type III CRISPR-Cas systems. Although we did not detect cross-utilization of type I-E and type I-F spacers by the type III-A system in *Serratia*, this potentially reflects the evolutionary divergence of type III-A from type III-B/C/D CRISPR-Cas systems. Type III-A systems typically contain their own CRISPR adaptation and processing factors, which are often lacking in type III-B/C/D systems ([@bib31]). The diversity of type III-B CRISPR-Cas configurations co-occurring with type I systems in *Marinomonas* species, and the presence of the chimeric type III/I-F system in *Marinomonas* sp. MWYL1 suggest that the use of type I crRNAs by type III-B effector modules is not limited to *M. mediterranea* MMB-1. The ability to borrow crRNAs from disparate CRISPR loci could explain why type III-B systems also often lack CRISPR arrays ([@bib31]). For example, a type III-B system lacking CRISPR arrays in *Sulfolobus islandicus* REY15A has been reported to utilize crRNAs from a type I-A locus for interference in vivo ([@bib7]). These type III systems might have lost their system-specific CRISPR arrays over time. Alternatively, we propose they could have been acquired by horizontal gene transfer as promiscuous 'backup' interference modules, adding an additional layer of support to the host type I systems. Consistent with this, genomic analyses of other *S. islandicus* strains revealed that while the type I-A locus is always present, modular reassortments of type III Cas modules are common ([@bib20]).

One hypothesis that might explain the difference between type III-A and other type III systems is that the effector complexes encoded by type III-B/C/D loci could possess a higher degree of plasticity in their crRNA selection criteria. Certainly, in *M. mediterranea* MMB-1, the type III-B effector complex can use its own type III-B associated arrays, but is also able to utilize information stored in the type I-F CRISPR array despite both loci possessing highly dissimilar repeat sequences. This plasticity could not be examined in previous studies ([@bib7]; [@bib10]) because the host genomes in those studies only contained type I CRISPR arrays with identical repeats. Future research will be required to determine the molecular requirements that enable plasticity in crRNA usage by type III systems. For instance, previous studies have documented the processing and tight interaction between Cas6f and mature crRNAs ([@bib18]; [@bib39]), suggesting the possibility of direct interactions between Cas6f and components of the type III-B Cmr complex. With well-characterized CRISPR adaptation and immunity pathways and an accessible habitat for the isolation of natural strains and parasites, *M. mediterranea* could serve as a valuable model system for interrogating such interactions. A high degree of plasticity in crRNA usage criteria would enhance the success of mobile genetic elements containing type III interference modules, as they could be beneficial immediately upon acquisition by a CRISPR-compatible host.

If widespread, plasticity in crRNA selection by type III interference modules could help to explain the frequent co-occurrence of type III and type I systems in prokaryotic genomes. In this regard, it is salient that we observed adherence of the type III self/non-self discrimination mechanism with type I-F crRNAs. This mechanism permits the 'universal' avoidance of self-targeting, without a specific sequence requirement such as a PAM, potentially allowing for broad non-specific crRNA use by type III-B systems. The emerging picture is one of fluid interactions between bacterial genomes and a diversity of mobile elements, including not only phage and plasmids but CRISPR-Cas systems as well ([@bib13]). Our findings demonstrate that longitudinal studies of CRISPR adaptation in ecological contexts ([@bib2]) could benefit from whole genome sequencing of highly-related host strains to identify horizontal transfer of complete CRISPR-Cas modules and de novo formation of chimeric systems.

Materials and methods {#s4}
=====================

High throughput sequencing data {#s4-1}
-------------------------------

All sequencing data generated in this study (SRP103952) were deposited at the NCBI Short Read Archive (SRA) and are additionally summarized in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Plasmid construction {#s4-2}
--------------------

The plasmid constructs used for spacer acquisition and in vivo pre-crRNA processing studies in *M. mediterranea* were described previously ([@bib45]). Plasmids for CRISPR interference assays were built on the pKT230 backbone (a gift from Prof. L. Banta, Williams College). Protospacer RNA transcription was driven by a constitutive beta-lactamase promoter (P~amp~) in pKT230. By high-throughput RNA sequencing we previously confirmed that this promoter drives efficient unidirectional transcription in MMB-1 (data not shown). Plasmids for the *Serratia* interference assays were based on the pPF781 backbone ([@bib36]). Protospacer RNA transcription was driven by the arabinose-inducible P~BAD~ promoter. All plasmids were verified by sequencing and are available upon request. Plasmid sequences are included in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Strains and culture conditions {#s4-3}
------------------------------

Mutant *M. mediterranea* MMB-1 strains were constructed in a spontaneous Rifampicin-resistant genetic background by allelic exchange mutagenesis using *sacB*/sucrose counter-selection with the pEX18Gm suicide vector backbone and the *E. coli* S17-1λpir donor strain as described previously ([@bib6]). The genomes of all mutant strains were verified by whole genome sequencing. Despite several attempts, we were unable to obtain strains with deletions of the *csy* genes.

All bacterial strains were stored at −80°C in 20% glycerol. Two clones (independent transconjugants) from each conjugation were tested for spacer acquisition and in vivo pre-crRNA processing assays. Plasmids were mobilized into *M. mediterranea* as previously described ([@bib47]). Transconjugants were selected on 2216 marine agar (Difco) with 50 μg/mL Kanamycin and 50 μg/mL Rifampicin at 25°C. For nucleic acid extraction, transconjugants were inoculated in 2 mL Km-broth (2216 marine medium (Difco) with 50 μg/mL Kanamycin) and shaken at 23--25°C for 4--8 hr. Cultures were immediately expanded in 15 mL Km-broth and grown for an additional 4--8 hr before nucleic acid extraction.

Nucleic acid extractions {#s4-4}
------------------------

This method is a slight modification of a previously published protocol for CRISPR spacer sequencing ([@bib45]); we have provided the protocol in entirety for completeness, retaining relevant text from the original protocol. Total RNA for in vivo spacer processing assays was extracted from 300 to 500 μL of 15 mL confluent cultures using TRIZOL reagent (Life Technologies) according to manufacturer's instructions, without any subsequent enzymatic treatments. The remaining 14.5 mL of culture was used for plasmid midiprep. Cells were harvested by centrifugation (4000 x g, 30 min, 4°C) and homogenized in 300 μL alkaline lysis buffer (40 mM glucose, 10 mM Tris, 4 mM EDTA, 0.1 N NaOH, 0.5% SDS) at 50°C by vortexing until clear (10--15 min). Chilled neutralization buffer (600 μL of 3 M CH~3~COOK, 2 M CH~3~COOH) was added and lysates were immediately transferred to ice to prevent digestion of genomic DNA. Samples were mixed by inverting and the genomic DNA containing precipitate was removed by centrifugation (20,000 x g, 20 min, 4°C). Clarified lysates were extracted twice with a 1:1 mixture of Tris-saturated-phenol (Life Technologies) and CHCl~3~ (Fisher Scientific), and once with CHCl~3~ in Heavy Phaselock Gel tubes (5 Prime). Isopropanol (950 μL) was added and the plasmid DNA was pelleted by centrifugation (16,000 x g, 20 min, 4°C), washed twice in 80% ethanol, and resuspended in 200 μL 1x NEB Cutsmart Buffer. Samples were treated with 50 μg/mL RNase A (Life Technologies) at 37°C for 30 min, linearized with PvuII-HF (NEB) at 37°C for 60 min (to aid denaturation during PCR), and treated with 200 μg/mL Protease K at 50°C for 30 min. Finally, each digest was purified using a Zymo gDNA Clean and Concentrator column.

Genomic DNA from MMB-1 strains was extracted using a modified SDS/Protease K method: cells from 300 to 500 μL confluent culture were resuspended in 200 μL lysis buffer (10 mM Tris, 10 mM EDTA, 400 μg/mL protease K, 0.5% SDS) and incubated at 42°C for 1 hr. The digest was purified using the gDNA Clean and Concentrator Kit (Zymo Research). DNA and RNA preparations were quantified using a Qubit 2.0 Fluorometer (Life Technologies).

Spacer acquisition assay {#s4-5}
------------------------

Assays were performed as described previously ([@bib45]). In figures S1 and S3, we used a Monte Carlo simulation to evaluate a null hypothesis based on random assortment of spacer acquisitions from genomic DNA, with no dependence on gene expression level. Simulations were performed as described previously ([@bib45]); for clarity, we provide relevant text from the original method here. For each system, a series of samples of 500 spacers each were randomly chosen in silico from a list of all genes based on the sizes of the individual genes using the stochastic universal sampling algorithm. Sets of 1000 such trials were used to generate a range of null relationships between gene expression and spacer acquisition. The Monte Carlo bounds (black dotted lines on the respective figures) depict the envelope of such simulated random assortments. Traces above this envelope indicate preferential spacer acquisition from highly expressed genes, whereas traces below the envelope indicate spacer acquisition from poorly expressed genes more often than expected by random chance. *M. mediterranea* MMB-1 expression data (at NCBI SRA: SRR2914032, SRR2914033) were previously generated by RNAseq ([@bib45]).

In vivo pre-crRNA processing assay {#s4-6}
----------------------------------

We used a protocol that preserves strand information, controls for PCR amplification bias, and faithfully reports the 3' ends of source RNA molecules. Total intact RNA (5--10 μg) was run under denaturing conditions on a 6% Novex TBE-Urea polyacrylamide gel (Life Technologies) at 180V for 35 min. Gel fragments corresponding to 30--80 nt size range were excised, and the small RNA fraction was eluted as follows. Gel fragments were shredded and soaked in RNA elution buffer (300 mM NaCl, 1 mM EDTA) overnight at 4°C, and fragments were removed from the eluate by filtration through 0.45 μm Corning Costar Spin-X sterile cellulose acetate filters (Sigma). RNA was precipitated by the addition of 1 ml ethanol, then pelleted by centrifugation (20,000 x g, 20 min, 4°C), and resuspended in RNase-free water. RNA sequencing libraries were prepared as described previously ([@bib45]). Sequencing reads containing the first 5 bases of the CRISPR repeat were trimmed, and trimmed reads comprising substrings of the CRISPR repeat sequence were identified. Trimmed reads shorter than 12 bases were also evaluated for a match between the 5 bases preceding the CRISPR repeat and the last 5 bases of genomic CRISPR spacer sequences. Length histograms of trimmed reads in libraries constructed from two independent transconjugant strains are shown for each experiment.

Plasmid interference assay {#s4-7}
--------------------------

The pKT230 vector backbone contains a Kanamycin resistance gene, which allowed us to assay for growth on selective medium as a proxy for CRISPR-Cas interference during the conjugative transfer of the plasmids into MMB-1. A protospacer configuration that allows the plasmid to be targeted by a CRISPR-Cas system leads to plasmid elimination and cell death on selective medium (+Kan). The number of colony forming units per mL of conjugation mixture was determined by dilution and plating on selective medium (2216 marine agar with 50 μg/mL Kanamycin and 50 μg/mL Rifampicin) at 25°C. To account for day-to-day variability in growth between MMB-1 cultures, all protospacer configurations for each host strain were tested on the same day. Plasmid interference in *Serratia* was measured using conjugation efficiency assays, as previously described ([@bib36]). The conjugation efficiency is reported as transconjugants/recipients.

Relative protospacer transcript level assay {#s4-8}
-------------------------------------------

This method is a slight modification of a previously published protocol for CRISPR spacer sequencing ([@bib45]); we have provided the protocol in entirety for completeness, retaining relevant text from the original protocol. To standardize the nucleic acid extraction, log-phase cultures of MMB-1 strains carrying pKT230 plasmids with each protospacer configuration (as in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) were pooled. RNA was extracted from the pooled samples using TRIZOL reagent and treated with TURBO DNase (Life Technologies) according to manufacturer's instructions. The DNase was subsequently removed by extracting the digests once with a 1:1 mixture of Tris-saturated-phenol (pH 8.0) and CHCl~3~, and once with CHCl~3~ in Heavy Phaselock Gel tubes (5 Prime). Purified RNA (2 μg) was reverse-transcribed into cDNA using Superscript III (Life Technologies), according to the high GC content protocol, with the gene-specific primer AF-SS-425 (TTCAGTTTTCTGATGAAGCGCGAAT). AF-SS-425 binds downstream of the protospacer sequence in a region of the vector backbone common to all plasmids in the mixture. cDNA was treated with RNase H and libraries were prepared for sequencing by a two round PCR method adapted from the spacer acquisition assay. The protospacer locus of the plasmid was amplified from the cDNA sample with primers binding to the same sites in all plasmid configurations, and assayed for the presence or absence of the various protospacer configurations by high throughput sequencing. Round 1 PCR was performed with primers AF-SS-426 (CGACGCTCTTCCGATCTNNNNN AGATGCTGAAGATCAGTTGG) and AF-SS-427 (ACTGACGCTAGTGCATCA AGAAATATCCCGAATGTGCA) as follows: (98°C, 1 min), 2x (98°C, 10 s; 52°C, 20 s; 72°C, 30 s), 16-19x (98°C, 15 s; 65°C, 15 s; 72°C, 30 s), (72°C, 9 min). This simultaneously generated amplicons of near-identical length from all protospacer constructs in a single reaction. Sequencing adaptors were then attached in a second round of PCR with 0.01 volumes of the previous reaction as template, using AF-SS-44:55 (CAAGCAGAAGACGGCATACGAGAT NNNNNNNN GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCACTGACGCTAGTGCATCA) and AF-KLA-67:74 (AATGATACGGCGACCACCGAGATCTACAC NNNNNNNN ACACTCTTTCCCTACACGACGCTCTTCCGATCT) where the (N)~8~ barcodes correspond to Illumina TruSeq HT indexes D701-D712 (reverse complemented), and D501-D508 respectively. Cycling conditions for this step were: (98°C, 1 min), 2x (98°C, 10 s; 54°C, 20 s; 72°C, 30 s), 3x (98°C, 15 s; 70°C, 15 s; 72°C, 30 s), (72°C, 9 min). Libraries were quantified by Qubit, and sequenced with Illumina MiSeq v3 kits (150 cycles, Read 1; 8 cycles, Index 1; 8 cycles, Index 2).

To verify that all the plasmids in the pooled culture samples used for RNA extraction (as above) were present at comparable levels, a portion of the each sample was reserved for DNA extraction and sequencing. Three mixtures were tested in separate experiments: a mixture of 8 strains in the Cmr2 GGAA mutant background, and two mixtures of 4 strains each in the WT and Cmr4 D26A mutant backgrounds. Relative protospacer RNA incidence is shown as the log~10~ of the number of RNA-derived sequencing reads normalized to the log~10~ of the number of identical DNA reads. This metric is comparable between the various plasmid configurations in a given experiment, but is not a measure of the transcript-to-template ratio in any individual cell because the RNA and DNA libraries were prepared separately and sequenced to similar depths. Controls lacking reverse transcriptase were included, and residual gDNA contamination in DNase treated RNA was determined by PCR titration to be negligible.

Phage enrichment and isolation {#s4-9}
------------------------------

Seawater and sediment samples in contact with *Posidonia oceanica* seagrass were collected from the Mediterranean coast of the Region of Murcia in South Eastern Spain. Samples were kept at 4°C and processed the day after collection by filtration through cotton cloth, pre-clearing by centrifugation (5000 x g for 10 min at 4°C), and another round of filtration through 0.45 μm mixed cellulose ester filters (Millipore).

Phage amplification was performed with methods adapted from ([@bib52]). The *M. mediterranea* ΔIII-B strain was used as the host for enrichment from seawater samples to avoid type III-B interference against putative phage infection, and the *M. mediterranea* T103 strain ([@bib28]) -- a histidine kinase mutant that exhibits increased sensitivity to CPG1g infection in addition to other physiological changes -- was used as the host for phage enrichment from sediment samples. The host strains were grown in MMC2G broth (NaCl 2%, MgSO~4~·7H~2~O 0.7%, MgCl~2~·6H~2~O 0.53%, KCl 0.07%, CaCl~2~·2H~2~O 0.125%, Peptone 0.5%, Yeast extract 0.1%, Iron (III) citrate hydrate 0.001%, Sodium citrate 0.009%, K~2~HPO~4~0.4 mM, Glucose 0.2%, pH 7.4). 20 ml of exponential phase cultures were added to 180 ml of seawater samples supplemented with peptone and yeast extract to final concentrations of 0.5% and 0.1% respectively (as in MMC2G). The enrichment cultures were shaken overnight (25°C, 130 rpm). Enrichment cultures were repeatedly sub-cultured in borosilicate tubes until the potential presence of phage was indicated by a decrease in the optical density relative to simultaneous cultures of the ΔIII-B strain without seawater. Finally, the cultures were sterile-filtered and plaque assays were performed with the respective host strains (∆III-B or T103) using the double layer agar technique with MMC2 medium (MMC2G with the glucose omitted). The top layer was prepared with 0.6% agar (Pronadisa) and the bottom with 0.8% agar.

Phage genome sequencing and annotation {#s4-10}
--------------------------------------

The genomes of two phage (CPG1g and CPP1m) that produced plaques of different sizes, and also of the phage isolated from sand samples (CB5A) were sequenced. Phage lysates (500 μL) were digested (10 mM Tris, 10 mM EDTA, 200 μg/mL protease K, 0.5% SDS) at 55°C for 30 min. The digests were extracted once with a 1:1 mixture of Tris-saturated-phenol and CHCl~3~, and once with CHCl~3~ in heavy Phaselock gel tubes (5 Prime). DNA sequencing libraries were prepared using the Illumina Nextera kit (Illumina), and sequenced with Illumina MiSeq v3 kits (150 cycles, Read 1; 8 cycles, Index 1; 8 cycles, Index 2). The phage genomes were assembled by SPAdes (3.7.1). Phage genomes were annotated using RAST (<http://rast.nmpdr.org/>) and PHAST (<http://phast.wishartlab.com/>). tRNA genes were detected using tRNA-scan SE2 (<http://trna.ucsc.edu/cgi-bin/tRNAscan-SE2.cgi>). Rho-independent terminators were analyzed using ARNold (<http://rna.igmors.u-psud.fr/toolbox/arnold/>).

The genomes of phage CPG1g (deposited in GenBank: KY626177) and CPP1m (deposited in GenBank: KY626176) differed at 7 sites: an insertion in position 1809 and 6 single nucleotide variants (SNVs). The insertion generated a frame shift in a 262 aa hypothetical protein (ARB11222) which led to a loss of 27 C-terminal residues (7 residues modified and 20 lost due to premature termination) relative to CPG1g (ARB11272). Only one of 6 SNVs resulted in a change at the protein level: a P448Q variant in the putative DNA primase/helicase (ARB11244 and ARB11284). The genome of phage CB5A was also deposited in GenBank: MF481197.

The 25 remaining phage isolates were tested by PCR to determine if they were likely to be variants of CPG1g. Primers targeting two conserved *Podoviridae* genes were utilized: DpG1gDIR (AACACTTTTAGGATGCGACATAAGT) and DpG1gREV (CCTGTCATCTGCAACAATACATTAAG) amplified a 478 bp portion of the phage DNA polymerase gene, and primers IcG1gDIR (TCACCTCGTGCGATGTTCTC) and IcG1gREV (CATCTCCTCACCTCCATGTTGG) amplified a 728 bp portion of the gene encoding phage protein inside capsid D. All 25 phage isolates produced expected amplicons in both reactions.

Viral DNA polymerase phylogenetic analysis {#s4-11}
------------------------------------------

Protein sequences similar to the DNA polymerase encoded in the *Marinomonas* phage CPG1g genome were selected by BLAST. Sequences were aligned using the CLUSTAL W algorithm. The MEGA 6 program was used to perform phylogenetic analyses. Trees were constructed using the Neighbor-Joining (NJ) and Maximum Likelihood methods. For the NJ tree, distances between sequences were computed using the p-distance method and are in the units of the number of amino acid differences per site. For the maximum Likelihood (ML) tree, the Le and Gascue substitution model was selected. A discrete Gamma distribution was used to model evolutionary rate differences among sites. Pairwise distances were estimated using a Jones-Taylor-Thorton (JTT) model. All positions with less than 95% coverage were eliminated (i.e. fewer than 5% alignment gaps, missing data, and ambiguous bases were allowed at any position). The reliability of each node in the trees was estimated using bootstrap analysis with 500 replicates.

*M. mediterranea* IVIA-Po-186 and CPR1 genome sequencing {#s4-12}
--------------------------------------------------------

Isolation of *M. mediterranea* IVIA-Po-186 was described previously ([@bib11]). *M. mediterranea* CPR1 was isolated from *Posidonia oceanica* plants in Cabo de Palos in July 2005. The roots were washed in sterile saline solution ([@bib46]), comminuted, and plated on Marine Agar 2216. Putative *M. mediterranea* strains were identified by their dark pigmentation in this medium. Genomic DNA extracted from IVIA-Po-186 and CPR1 was prepared for high-throughput sequencing using the Nextera DNA Library Prep Kit (Illumina). Contigs were assembled using spades 3.7.1 in 'careful' mode (including read error correction in addition to assembly).

Evolution experiments to assess inhibition of phage escape by the type III-B system {#s4-13}
-----------------------------------------------------------------------------------

Log-phase cultures of WT and ∆III-B strains were inoculated with phage CB5A at MOI of 10^−2^, 10^−4^, and 10^−6^, and grown without shaking at 25°C overnight. All WT infected cultures showed bacterial growth, but only a slight turbidity was observed for the 10^−6^ MOI infection of the ∆III-B strain (whereas 10^−2^ and 10^−4^ MOI infections were lysed). The 10^−6^ MOI infected cultures of both strains were clarified by centrifugation at 6000 x g, and a 10 µL inoculum of the phage-containing supernatant was used to infect fresh host cells as before. After overnight incubation, the WT infected cultures again showed growth, but the ∆III-B cultures did not, indicating phage-mediated lysis of host cells. The supernatant was clarified by centrifugation, and phage titers were determined on the WT, ∆III-B, and ∆I-F∆III-B indicator strains using the Most Probable Number (MPN) method ([@bib25]). The experiment with the WT host strain was repeated 3 times, whereas 6 replicates of the evolution experiment were performed with the ∆III-B host. Plaque sizes were also determined on lawns of the ∆III-B strain, and genomes of 2 phage isolates from each of the 6 independent trials producing large plaques were sequenced as described above.
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###### Summary of all high-throughput sequencing data generated for this study.

10.7554/eLife.27601.022

###### Sequences of the plasmids used in this study.

Names of plasmids used for interference assays specify whether the protospacers match spacers from the type III-B or I-F CRISPR arrays. RC denotes that the reverse complement of a particular configuration was used. DR signifies that the protospacer was flanked by CRISPR repeats of the same array as the spacers.
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Major datasets {#s7}
--------------

The following dataset was generated:

Silas SLucas-Elio PJackson SAFineran PCFire AZSanchez-Amat A2017CRISPR targeting and spacer acquisition in M. mediterranea mutants, and associated environmental investigations<https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103952>Publicly accessible at NCBI Sequence Read Archive (accession no. SRP103952)

The following previously published datasets were used:

Silas SMohr GSidote DJMarkham LMSanchez-Amat ABhaya DLambowitz AMFire AZ2016total RNA (\> 200 nt) sequencing from MMB-1 strains over-expressing RT-Cas1, Cas2, and Marme_0670 - replicate 1<https://www.ncbi.nlm.nih.gov/sra/?term=SRR2914032>Publicly accessible at NCBI Sequence Read Archive (accession no. SRR2914032)

Silas SMohr GSidote DJMarkham LMSanchez-Amat ABhaya DLambowitz AMFire AZ2016total RNA (\> 200 nt) sequencing from MMB-1 strains over-expressing RT-Cas1, Cas2, and Marme_0670 - replicate 2<https://www.ncbi.nlm.nih.gov/sra/?term=SRR2914033>Publicly accessible at NCBI Sequence Read Archive (accession no. SRR2914033)

10.7554/eLife.27601.030

Decision letter

Wiedenheft

Blake

Reviewing Editor

Montana State University

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Mobile type III CRISPR-Cas systems can provide redundancy to counteract viral escape from type I systems\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom served as Guest Reviewing Editor, and the evaluation has been overseen by Gisela Storz as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Edze Westra (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Work by these authors previously showed that the Type III-B system in M. mediterranea MMB-1 is capable of acquiring new spacers from RNA by using an RT-Cas1 fusion protein. Here they extend this work to address questions related to the orientation of newly integrated spacers, the mechanism(s) of target degradation by the I-F and III-B systems, the promiscuity of sharing spacers between these systems, and speculate on the selective pressures that would explain the co-occurrence of these two systems. The referees agree that the work is generally well-performed but the novelty is substantially overstated.

Essential revisions:

1\) Claims that the work presents unique and new insights into CRISPR biology are largely overstated and these claims should be revised to more accurately reflect the contribution of previous work.

2\) The rather poor immunity provided by the type III-B system when using the type I-F spacer, indicates that type III-B-mediated interference using a type I-F-derived spacer is impaired. It is critical that type III-B-mediated phage defense is measured with spacers derived from its own type III-B array. In addition, RNA-seq from pull-down type I-F and III-B complexes should be used to corroborate that type I-F crRNAs are also present in the type III-B complex but not vice versa.

3\) The authors state that the type III-B system provides an additional layer of protection. However, all experiments are performed using fixed genotypes. To demonstrate that type III limits phage escape, we recommend evolutionary experiments. Phage challenge of cells with a wild type immune system (i.e. I-F and III-B), as well as the isogenic mutant lacking III-B, would allow the authors to test the hypothesis by looking for phage escape mutants after 1, 2 and 3 days.

4\) The authors describe a scenario that might explain the selective force that caused the III-B and I-F systems to end up in the same host. However, the sparse genomic data used is not convincing and the proposed scenario seems contrived. This section of the paper should be moved to the Discussion.

5\) Repeat spacer analysis in [Figure 2](#fig2){ref-type="fig"} with spacers acquired from plasmids.

Title:

The title is inaccurate because there is little proof of the mobility of the studied type III-B system. The title is also confusing because it gives the impression that the investigators are reporting experiments about the transfer of the type III system, for example via conjugation or another form of gene transfer route.

10.7554/eLife.27601.031

Author response

*Essential revisions:*

*1) Claims that the work presents unique and new insights into CRISPR biology are largely overstated and these claims should be revised to more accurately reflect the contribution of previous work.*

We have carefully revised the text to ensure that the novel aspects of our study are clear in the context of previous work in the field. Specifically, identifying a deficiency in type III spacer acquisition (the apparent lack of a mechanism to correctly orient new spacers in the CRISPR loci), the plasticity of crRNA utilization by type III interference machinery (as it is able to utilize crRNAs with diverse CRISPR repeats), the biological function of crRNA-stealing (or sharing) among cohabiting CRISPR-Cas systems (including type III-style self- non-self- discrimination with type I-F crRNAs), and the physiological consequences of this in the native host ecosystem (providing defense against phage that escape type I-F immunity and suppressing proliferation of such mutants).

In terms of the specific history of utilization of the same crRNAs by different CRISPR-Cas systems, we have expanded our introductory discussion of several studies in which co-precipitation analyses suggested some cross-association between RNAs and various interference complexes (Staals et al., 2013; Staals et al., 2014; Elmore et al., 2015; Majumdar et al., 2015), and the studies by Deng et al., 2013 and Elmore et al., 2016 that provided the first evidence of functional "crRNA sharing" from "communal" arrays using engineered plasmids. These indications spark considerable interest in the possibility that such immunological redundancy might be effective in a natural ecosystem. With some new data, we provide explicit evidence (below) that promiscuous crRNA use by the type III-B system in *M. mediterranea* MMB-1 provides PAM-independent backup to type I-F CRISPR-Cas immunity against naturally occurring phages that have PAM mutations allowing them to escape type I-F interference. We hope the revised manuscript provides a clearer description of the unique new insights of our work in the context of the existing literature.

We have also clarified another significant aspect of the cooperation between CRISPR systems, related to the architecture of the CRISPR-Cas systems. Type III systems (such as the type III-B loci in *S. islandicus* REY15A used by Deng et al., and the type III-B loci in *P. furiosus* used by Elmore et al.) often lack CRISPR arrays, as well as components for acquisition of spacers (i.e. *cas1* and *cas2*) and for crRNA processing and maturation (i.e. *cas6*). The earlier data were consistent with models (certainly still plausible) that different systems co-habiting the same host might potentially share 'communal' CRISPR arrays, with the systems having co-evolved to use identical CRISPR repeat sequences for crRNA selection and loading onto the interference machinery. In contrast, the type III-B system in *M. mediterranea* MMB-1 has evidently been recently acquired (relative to the type I-F system that is conserved in very closely related *M. mediterranea* strains, whereas the type III-B systems differ both in sequence and genomic context) and contains its own components for each step of the CRISPR immunity pathway, including CRISPR arrays that we demonstrate are specific to the type III-B system (yielding precursor crRNAs that can only be processed by type III-B factors). The observation that the *M. mediterranea* MMB-1 type III-B system can also use type I-F crRNAs, shows an opportunistic and potentially adaptive flexibility to both own and borrow guides, and establishes an entirely new model of plasticity in crRNA selection by the type III interference machinery.

The key points here have been substantially strengthened in the revised manuscript through the isolation and sequencing of an additional phage, and through characterization of the corresponding infectivity patterns in laboratory evolution experiments. We hope that we have now better articulated how these findings fit within, and extend, the context of previous work -- in particular, the previously enigmatic co-occurrence of type III and type I systems.

Please also refer to our response to point 4.

*2) The rather poor immunity provided by the type III-B system when using the type I-F spacer, indicates that type III-B-mediated interference using a type I-F-derived spacer is impaired. It is critical that type III-B-mediated phage defense is measured with spacers derived from its own type III-B array. In addition, RNA-seq from pull-down type I-F and III-B complexes should be used to corroborate that type I-F crRNAs are also present in the type III-B complex but not vice versa.*

We now explain this in more detail in the paper. Multiple lines of evidence support a substantially effective immune response by the type III-B system. This should now be clearer, both from more explicit explanation and some additional data in the paper.

Immunity can be measured on a variety of scales, and the immunity provided by the type III-B system using the type I-F spacers is substantial in each of the individual assays. Our plasmid inference assays provide a direct comparison for the type III-B system using its own spacers versus type I-F spacers. In both cases we observed at least a two order-of-magnitude decrease in plasmid conjugation efficiency. (E.g. compare results of the plasmid interference assay with the ∆I-Fcas123 strain (only type III interference possible in this strain) in [Figure 1C](#fig1){ref-type="fig"} (type III interference using spacers from the type III-B array) and [Figure 3E](#fig3){ref-type="fig"} (type III interference using spacers from the type I-F array). To make the corollary argument: that anti-plasmid type I and type III interference efficiencies are similar, compare type III interference using type I spacers in the ∆I-Fcas123 strain (only type III interference possible, [Figure 3E](#fig3){ref-type="fig"}) with PAM-enabled type I interference using type I spacers in the ∆III-B strain (only type I interference possible, [Figure 5C](#fig5){ref-type="fig"})). Because different spacer sequences provide differing levels of immunity, even within the same system (e.g. Xue, NAR 2015), we had performed the experiments in [Figures 1C](#fig1){ref-type="fig"}, [3E](#fig3){ref-type="fig"}, and 5C-D with two examples of each spacer type.

In regards to phage defense, although the \~10 fold increase in CPG1g phage EOP observed in the absence of the type III-B system might appear modest, this is still greater than the immunity provided by the type I-F system (owing to the PAM and protospacer mutations in the phage) -- representing a fitness advantage for strains possessing the type III-B system (see also our response to the reviewers' point 4). Moreover, plaque formation is a complex process dependent on several factors (e.g. the host growth rate, phage burst time and size) and the absolute difference in plaque numbers (EOP) provides only one metric of immunity. As such, we now emphasize both the EOP and plaque size (e.g. larger plaques are formed in the absence of type III-B immunity, [Figure 3](#fig3){ref-type="fig"}).

An additional set of arguments comes from our isolation of a new phage, CB5A, which is targeted by the *M. mediterranea* MMB-1 type I-F system with a canonical PAM (GG) (see also our response to reviewers' point 3). This has enabled us to present a broader examination of the role type I-F spacers play in phage immunity, and to directly address the reviewers' concern that type III immunity relative to type I anti-phage defense is somehow impaired. When we examined efficiency of plaquing for CB5A, we observed that knockout of the type III-B system increases the EOP \>1000 fold, whereas the knockout of type I-F interference (the *cas1, cas2-3* deletion strain) only increases the EOP \~50 fold (note that the type I-F system can only use one spacer to target CB5A, compared with multiple type I-F derived spacers used by the type III-B system). The differences between CB5A and CPG1g infectivity ([Figures 3D](#fig3){ref-type="fig"} and [7B](#fig7){ref-type="fig"}) in the presence or absence of various CRISPR-Cas components highlight that the type III-B system provides robust anti-phage defense using type I-F crRNAs, and likely reflect the evolutionary divergence of these phage, driven by host CRISPR-Cas immunity (see also the expanded Results section "The type III-B CRISPR-Cas system counteracts viral escape from the type I-F system").

In response to the second point of the reviewer's comment (that RNAseq from pull-downs of the type I-F and type III-B complexes should be performed) we feel that although it might be nice to include complementary data such as this, it would not provide any additional biological insights beyond what we have extensively demonstrated with functional assays in vivo. Given the strong functional evidence ([Figures 1C](#fig1){ref-type="fig"}, [3E](#fig3){ref-type="fig"}, [5C-D](#fig5){ref-type="fig"}; of particular note, assays indicating that type III interference using type I-F spacers requires multiple type III-B components including Cmr2, Cmr4, and the GGDD motif in Cmr2) and challenges in interpreting co-precipitation data (e.g. non-specific RNA-protein binding could occur even in the absence of a functional interaction; conversely,the lack of an association in a co-immunoprecipitation assay would not provide a reliable assessment of the lack of an interaction in vivo), we consider these experiments to be beyond the scope of this study.

*3) The authors state that the type III-B system provides an additional layer of protection. However, all experiments are performed using fixed genotypes. To demonstrate that type III limits phage escape, we recommend evolutionary experiments. Phage challenge of cells with a wild type immune system (i.e. I-F and III-B), as well as the isogenic mutant lacking III-B, would allow the authors to test the hypothesis by looking for phage escape mutants after 1, 2 and 3 days.*

We share the reviewer's enthusiasm for these laboratory-evolution type experiments. We were initially precluded from performing these, due to the lack of a phage-host combination where the host possessed type I-F--specific immunity against the phage (due to the PAM mutations in CPG1g). We investigated 'engineering' a relationship in our phage-host setup, but this would be impractical. Fortunately, we were able to address this point by isolating another new phage from the marine environment. We performed additional phage isolations from sediment samples obtained from Mediterranean sea-grass meadows in Calabardina (Aguilas, Spain) using a previously isolated *M. mediterranea* strain with a histidine kinase mutation that renders the host more sensitive to CPG1g infection (in addition to altering the regulation of other physiological processes such as melanin synthesis). The new phage, designated CB5A, is closely related to CPG1g and may more closely represent an ancestor of phage CPG1g. This phage contains an intact PAM next to a protospacer that perfectly matches the second native spacer in the type I-F CRISPR04 array in the MMB-1 genome. The intact PAM implies that this protospacer would be recognized by both the type I-F and III-B systems. Consistent with this expectation, it produces small plaques on lawns of the ∆I-F Cas123 strain (i.e. lacking type I-F interference), or the ∆III-B strain (lacking type III-B interference; note that CPG1g -- an "escape" phage itself -- produces large plaques on this strain ([Figure 3B](#fig3){ref-type="fig"})). Phage CB5A was passaged on WT and ∆III-B strains with the addition of fresh host cells daily at each sub-culturing step, and mutant phage escaping the type I-F system arose after just one re-inoculation on the ∆III-B host, but not with the WT -- providing evidence that the ability of the III-B system to use I-F crRNAs reduces the proliferation of "escape" phages.

Eleven CB5A escape mutants from 6 independent evolution experiments were isolated and characterized by whole genome sequencing: all contained deletions or mutations of the PAM-containing protospacer. These phage isolates were also shown to match the CPG1g "escape" plaquing phenotype (i.e. large plaques on the ∆III-B host) instead of the CB5A phenotype (small plaques on the ∆III-B host). These results are described in the new [Figure 7](#fig7){ref-type="fig"} and its supplements, and are congruent with our model that the type III-B system helps to counter phages that escape type I-F defenses, thereby providing a fitness advantage to the host. We thank the reviewers for suggesting we pursue this experiment as we consider that this has added significant evolutionary context for our findings.

*4) The authors describe a scenario that might explain the selective force that caused the III-B and I-F systems to end up in the same host. However, the sparse genomic data used is not convincing and the proposed scenario seems contrived. This section of the paper should be moved to the Discussion.*

We thank the reviewers for the feedback on this section. It is our view that the genomic sequencing and comparative genomics data in this section are a critical part of the narrative. We have also clarified this in the reworked discussion of this section.

To better convey the close genetic relationship between the *M. mediterranea* strains that we sequenced as part of this study, we have performed average nucleotide identity (ANI) analyses to definitively establish relationships between these isolates of *M. mediterranea.* From this analysis, it is clear that theseare very closely related strains of the same species that exhibit remarkable differences between the type III CRISPR-Cas loci that they possess and/or lack. One of the key differences between our study and previous work, is that past studies (e.g. Deng et al., 2013, Elmore et al., 2016) suggest a model where type III systems stably co-reside with type I loci to provide redundancy or prevent evasion by anti-CRISPRs or phage escape mutants. We demonstrate that type III systems can indeed provide immunological redundancy in nature, with the genomic data presented in this section of our paper leading strongly to a model in which type III-B systems in *M. mediterranea* were more recently acquired than the type I-F system (which is conserved in all sequenced *M. mediterranea* strains). Thus, a more dynamic situation occurs in natural populations of *M. mediterranea*, whereby uptake and/or loss of diverse type III modules could be selected for by pressures arising in the course of the phage-host arms race. We propose that the apparent horizontal mobility of type III CRISPR interference modules even in closely related bacterial genomes (shown here for *Marinomonas* species, and also previously observed for strains of *S. islandicus* by Held et al., 2013) is advantageous due to their ability to use crRNAs from type I CRISPR loci, rather than a sign of their dependence on type I systems. In addition, as detailed in our earlier responses, our new data provide experimental evidence that the MMB-1 type III-B system suppresses proliferation of phage mutants that might otherwise have escaped type I-F defenses -- supporting a selective advantage for III-B systems through co-opting type I-F crRNAs.

*5) Repeat spacer analysis in [Figure 2](#fig2){ref-type="fig"} with spacers acquired from plasmids.*

We have performed these analyses as recommended. Despite the acquired spacer counts from plasmid being low, the binary relationships between the sense and antisense fractions were maintained in all experiments (with one exception, ∆Cmr4, likely a statistical anomaly from the low plasmid-derived-spacer counts). As nothing unexpected arose from this analysis, we would prefer to omit these results from the figures to avoid potential, unnecessary overwhelming of readers. See [Author response image 1](#respfig1){ref-type="fig"}.

![(As in [Figure 2](#fig2){ref-type="fig"}) Proportion of newly acquired spacers isolated from CRISPR03 mapping to sense and antisense strands of plasmid-borne genes.](elife-27601-resp-fig1){#respfig1}

*Title:*

*The title is inaccurate because there is little proof of the mobility of the studied type III-B system. The title is also confusing because it gives the impression that the investigators are reporting experiments about the transfer of the type III system, for example via conjugation or another form of gene transfer route.*

We are grateful to the reviewer for this observation. Certainly, the intent was not to mislead the readership as to the nature of experiments performed. We have modified the title accordingly.
